Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16,230 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial.
Watanabe T, Sano M, Takashima S, Kitaya T, Tokuda Y, Yoshimoto M, Kohno N, Nakagami K, Iwata H, Shimozuma K, Sonoo H, Tsuda H, Sakamoto G, Ohashi Y. Watanabe T, et al. J Clin Oncol. 2009 Mar 20;27(9):1368-74. doi: 10.1200/JCO.2008.18.3939. Epub 2009 Feb 9. J Clin Oncol. 2009. PMID: 19204202 Clinical Trial.
Relationships between pathological factors and long-term outcomes in patients enrolled in two prospective randomized controlled trials comparing the efficacy of oral tegafur-uracil with CMF (N·SAS-BC 01 trial and CUBC trial).
Ohno S, Saji S, Masuda N, Tsuda H, Akiyama F, Kurosumi M, Shimomura A, Sato N, Takao S, Ohsumi S, Tokuda Y, Inaji H, Watanabe T, Ohashi Y. Ohno S, et al. Among authors: watanabe t. Breast Cancer Res Treat. 2021 Feb;186(1):135-147. doi: 10.1007/s10549-020-06018-1. Epub 2020 Dec 1. Breast Cancer Res Treat. 2021. PMID: 33259001 Free PMC article.
Validation of a nuclear grading system for resected stage I-IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial.
Tsuda H, Kurosumi M, Akiyama F, Ohno S, Saji S, Masuda N, Shimomura A, Sato N, Takao S, Ohsumi S, Tokuda Y, Inaji H, Watanabe T. Tsuda H, et al. Among authors: watanabe t. Breast Cancer. 2022 Jul;29(4):720-729. doi: 10.1007/s12282-022-01350-4. Epub 2022 Apr 18. Breast Cancer. 2022. PMID: 35435571 Free PMC article.
NSAS-BC02 substudy of chemotherapy-induced amenorrhea (CIA) in premenopausal patients who received either taxane alone or doxorubicin(A) cyclophosphamide(C) followed by taxane as postoperative chemotherapy.
Iwamoto T, Hara F, Uemura Y, Mukai H, Watanabe T, Ohashi Y. Iwamoto T, et al. Among authors: watanabe t. Breast Cancer Res Treat. 2020 Jul;182(2):325-332. doi: 10.1007/s10549-020-05692-5. Epub 2020 May 28. Breast Cancer Res Treat. 2020. PMID: 32462261 Free article. Clinical Trial.
Efficacy of oral tegafur-uracil (UFT) as adjuvant therapy as compared with classical cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in early breast cancer: a pooled analysis of two randomized controlled trials (N.SAS-BC 01 trial and CUBC trial).
Ohashi Y, Watanabe T, Sano M, Koyama H, Inaji H, Suzuki T. Ohashi Y, et al. Among authors: watanabe t. Breast Cancer Res Treat. 2010 Feb;119(3):633-41. doi: 10.1007/s10549-009-0635-3. Breast Cancer Res Treat. 2010. PMID: 19936917 Clinical Trial.
16,230 results
You have reached the last available page of results. Please see the User Guide for more information.